Recovery of Unrelated Donors of Peripheral Blood Stem Cells versus Recovery of Unrelated Donors of Bone Marrow: A Prespecified Analysis from the Phase.

Slides:

Advertisements

Similar presentations

Alexander H. Schmidt, Thilo Mengling, Camila J

Advertisements

Adverse Clinical Consequences of Hyperglycemia from Total Parenteral Nutrition Exposure during Hematopoietic Stem Cell Transplantation Patricia M. Sheean,

Related PBSC Donors Age >60 Have High Rates of Baseline and Donation-Related Pain and Slow Recovery: First Report from the Related Donor Safety Study.

Mohamed A. Kharfan-Dabaja, Claudio Anasetti, Edgardo S. Santos

How to Treat MDS without Stem Cell Transplantation

Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program by Michael.

The Effect of the Composition of Unrelated Donor Bone Marrow and Peripheral Blood Progenitor Cell Grafts on Transplantation Outcomes Nancy H. Collins,

Vaccination of Children following Allogeneic Stem Cell Transplantation

Analysis of the Effect of Race, Socioeconomic Status, and Center Size on Unrelated National Marrow Donor Program Donor Outcomes: Donor Toxicities Are.

Recovery and Safety Profiles of Marrow and PBSC Donors: Experience of the National Marrow Donor Program John P. Miller, Elizabeth H. Perry, Thomas H.

Health-related Quality of Life of Bone Marrow versus Peripheral Blood Stem Cell Donors: A Prespecified Subgroup Analysis from a Phase III RCT—BMTCTN Protocol.

Randomized, Double-Blind, Placebo-Controlled Trial of Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Idiopathic Pneumonia.

Randomized Phase III Trial of Pegfilgrastim versus Filgrastim after Autologus Peripheral Blood Stem Cell Transplantation Aaron Gerds, Mary Fox-Geiman,

Influence of Stem Cell Source on Outcomes of Allogeneic Reduced-Intensity Conditioning Therapy Transplants Using Haploidentical Related Donors Kenneth.

National Marrow Donor Program HLA Matching Guidelines for Unrelated Adult Donor Hematopoietic Cell Transplants Robert A. Bray, Carolyn K. Hurley, Naynesh.

Pain, Donation-Related Symptoms and the Trajectory of Recovery in Children after Bone Marrow (BM) Donation Are Influenced By Age (Pre vs. Post-Puberty)

Adverse Clinical Consequences of Hyperglycemia from Total Parenteral Nutrition Exposure during Hematopoietic Stem Cell Transplantation Patricia M. Sheean,

Twenty Years of Unrelated Donor Hematopoietic Cell Transplantation for Adult Recipients Facilitated by the National Marrow Donor Program Chatchada Karanes,

Comparison of Outcomes after HLA-Matched Sibling and Unrelated Donor Transplantation for Children with High-Risk Acute Lymphoblastic Leukemia Mei-Jie.

Related PBSC Donors Experience Higher Levels of Pain and Donation-Related Symptoms and Less Complete Rates of Recovery Compared to Unrelated Donors:

Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemia Vivian.

Peripheral Blood Grafts from Unrelated Donors Are Associated with Increased Acute and Chronic Graft-versus-Host Disease without Improved Survival Mary.

Navneet S. Majhail, Elizabeth A. Murphy, Nancy A

The Blood and Marrow Transplant Clinical Trials Network: An Effective Infrastructure for Addressing Important Issues in Hematopoietic Cell Transplantation

Decision Analysis of Peripheral Blood versus Bone Marrow Hematopoietic Stem Cells for Allogeneic Hematopoietic Cell Transplantation Joseph Pidala, Claudio.

More Infections with Transplantation of Bone Marrow, Versus Peripheral-Blood Stem Cells, from Unrelated Donors Jo-Anne H. Young, MD, Brent R. Logan,

Jo-Anne H. Young, Brent R. Logan, Juan Wu, John R. Wingard, Daniel J

J. J. Nietfeld, Marcelo C. Pasquini, Brent R

Motivations, Experiences, and Perspectives of Bone Marrow and Peripheral Blood Stem Cell Donors: Thematic Synthesis of Qualitative Studies Maria C. Garcia,

Lymphocyte Phenotype during Therapy for Acute Graft-versus-Host Disease: A Brief Report from BMT-CTN 0302 Javier Bolaños-Meade, Juan Wu, Brent R. Logan,

Ofatumumab in Combination with Glucocorticoids for Primary Therapy of Chronic Graft- versus-Host Disease: Phase I Trial Results Joseph Pidala, Jongphil.

Twenty Years of Unrelated Donor Bone Marrow Transplantation for Pediatric Acute Leukemia Facilitated by the National Marrow Donor Program Margaret L.

Significant Improvement in Survival after Unrelated Donor Hematopoietic Cell Transplantation in the Recent Era Navneet S. Majhail, Pintip Chitphakdithai,

John R. Wingard, M. D. , Alan K. Leahigh, Dennis Confer, M. D

Plerixafor Plus Granulocyte Colony-Stimulating Factor versus Placebo Plus Granulocyte Colony-Stimulating Factor for Mobilization of CD34+ Hematopoietic.

Decreased Infections in Recipients of Unrelated Donor Hematopoietic Cell Transplantation from Donors with an Activating KIR Genotype Marcie Tomblyn,

Correlation between the numbers of naive T cells infused with blood stem cell allografts and the counts of naive T cells after transplantation Jan Storek,

B Cells and Transplantation: An Educational Resource

High White Blood Cell Concentration in the Peripheral Blood Stem Cell Product Can Induce Seizures during Infusion of Autologous Peripheral Blood Stem.

Joseph Pidala, Stephanie J

Sarah A. Holstein, Paul G. Richardson, Jacob P. Laubach, Philip L

Allogeneic Hematopoietic Stem Cell Transplantation in Adult Acute Lymphocytic Leukemia: Impact of Donor Source on Survival Priya Kumar, Todd E. Defor,

Frederick R. Appelbaum, Claudio Anasetti, Joseph H

Pharmacokinetic Evaluation of the Drug Interaction between Intravenous Itraconazole and Intravenous Tacrolimus or Intravenous Cyclosporin A in Allogeneic.

Predonation Health-Related Quality of Life Scores Predict Time to Recovery in Hematopoietic Stem Cell Donors Annelies Billen, J. Alejandro Madrigal,

Biology of Blood and Marrow Transplantation

Adverse Prognostic Factors for Morbidity and Mortality During Peripheral Blood Stem Cell Mobilization in Patients with Light Chain Amyloidosis Jason.

Race and Ethnicity Influences Collection of Granulocyte Colony–Stimulating Factor– Mobilized Peripheral Blood Progenitor Cells from Unrelated Donors, a.

Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data Brent R. Logan, Mei-Jie Zhang,

Tbo-Filgrastim versus Filgrastim during Mobilization and Neutrophil Engraftment for Autologous Stem Cell Transplantation Mohammed M. Elayan, Justin G.

What is quality in a transplant program?

Chronic Graft-Versus-Host Disease (cGVHD) following Unrelated Donor Hematopoietic Stem Cell Transplantation (HSCT): Higher Response Rate In Recipients.

A Randomized Controlled Trial to Compare Once- versus Twice-Daily Filgrastim for Mobilization of Peripheral Blood Stem Cells from Healthy Donors Yukiko.

Richard Mitchell, John E. Wagner, Claudio G

Chimeric Antigen Receptor–Modified T Cells: Clinical Translation in Stem Cell Transplantation and Beyond Stanley R. Riddell, Michael C. Jensen, Carl.

HLA-Allele Matched Unrelated Donors Compared to HLA-Matched Sibling Donors: Role of Cell Source and Disease Risk Category Ann Woolfrey, Stephanie J.

Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD–Positive Acute Myelogenous Leukemia: The Role for FLT3 Tyrosine Kinase Inhibitors Post-

Unrelated Donor Hematopoietic Cell Transplantation: Factors Associated with a Better HLA Match Jason Dehn, Mukta Arora, Stephen Spellman, Michelle Setterholm,

Blood and Marrow Transplant Handbook

Donation Activities and Product Integrity in Unrelated Donor Allogeneic Hematopoietic Transplantation: Experience of the National Marrow Donor Program

Low Serum Levels of Total Rabbit-IgG Is Associated with Acute Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation:

Mammen Chandy Biology of Blood and Marrow Transplantation

Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program.

Pain. Pain. (A) Skeletal pain experienced by bone marrow (BM) and peripheral blood stem cell (PBSC) donors at baseline, during the pericollection period,

Classification of HLA-Matching for Retrospective Analysis of Unrelated Donor Transplantation: Revised Definitions to Predict Survival Daniel Weisdorf,

Mary Eapen Biology of Blood and Marrow Transplantation

Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?

In Memoriam: E. Donnall Thomas

Optimal Donor Selection: Beyond HLA

Donor Experiences of Second Marrow or Peripheral Blood Stem Cell Collection Mirror the First, but CD34+ Yields Are Less David F. Stroncek, Bronwen E.

Presentation transcript:

Recovery of Unrelated Donors of Peripheral Blood Stem Cells versus Recovery of Unrelated Donors of Bone Marrow: A Prespecified Analysis from the Phase III Blood and Marrow Transplant Clinical Trials Network Protocol 0201 Linda J. Burns, Brent R. Logan, Pintip Chitphakdithai, John P. Miller, Rebecca Drexler, Stephen Spellman, Galen E. Switzer, John R. Wingard, Claudio Anasetti, Dennis L. Confer Biology of Blood and Marrow Transplantation Volume 22, Issue 6, Pages 1108-1116 (June 2016) DOI: 10.1016/j.bbmt.2016.02.018 Copyright © 2016 The American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Probability of complete recovery by donation of peripheral blood stem cells (PBSC) or bone marrow (BM). (A) All donors, 2004-2005. (B) All donors, 2006-2007. (C) All donors, 2008-2009. (D) Domestic donors, 2004-2005. (E) Domestic donors, 2006-2007. (F) Domestic donors, 2008-2009. Biology of Blood and Marrow Transplantation 2016 22, 1108-1116DOI: (10.1016/j.bbmt.2016.02.018) Copyright © 2016 The American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Skeletal pain and body symptoms by donation of peripheral blood stem cells (PBSC) or bone marrow. (A) Skeletal pain experienced by all donors by product at baseline and after donation. (B) Skeletal pain of domestic donors by product at baseline, peri-collection, and after donation. (C) Highest toxicity level across all body symptoms experienced by all donors by product at baseline and after donation. (D) Highest toxicity level across all body symptoms by domestic donors by product at baseline, peri-collection, and after donation. (E) Fatigue of all donors product at baseline and after donation. (F) Fatigue by domestic donors by product at baseline, peri-collection, and after donation. Peri-collection time points are day 5 of filgrastim administration for PBSC donors and day 2 after BM collection. Biology of Blood and Marrow Transplantation 2016 22, 1108-1116DOI: (10.1016/j.bbmt.2016.02.018) Copyright © 2016 The American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 Box and whiskers plots of (A) white blood cell (WBC) counts, (B) neutrophil counts, (C) mononuclear cell counts, (D) hemoglobin, and (E) platelet counts, by randomized product of peripheral blood stem cells (PBSC) or bone marrow, showing the maximum, upper quartile, median, lower quartile, and minimum values at baseline and the indicated time after donation: day of collection, 1 and 6 months, and 1 and 2 years. Biology of Blood and Marrow Transplantation 2016 22, 1108-1116DOI: (10.1016/j.bbmt.2016.02.018) Copyright © 2016 The American Society for Blood and Marrow Transplantation Terms and Conditions